Buchumschlag

AraC-based pharmacotherapy of chronic myeloid leukaemia

In interferon-α (IFN) treated chronic phase chronic myeloid leukaemia (CML) patients, survival depends on individual risk profile and achievement of a complete haematological response (CHR) and a major cytogenetic response (MCR) (< 35% Philadelphia-chromosome-positive metaphases). The highest cyt...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Hauptverfasser: Reiter, Andreas (VerfasserIn) , Hochhaus, Andreas (VerfasserIn) , Berger, Ute (VerfasserIn) , Kuhn, Christian (VerfasserIn) , Hehlmann, Rüdiger (VerfasserIn)
Dokumenttyp: Article (Journal)
Sprache:Englisch
Veröffentlicht: 2001
In: Expert opinion on pharmacotherapy
Year: 2001, Jahrgang: 2, Heft: 7, Pages: 1129-1135
ISSN:1744-7666
DOI:10.1517/14656566.2.7.1129
Online-Zugang:Verlag, lizenzpflichtig, Volltext: https://doi.org/10.1517/14656566.2.7.1129
Volltext
Verfasserangaben:Andreas Reiter, Andreas Hochhaus, Ute Berger, Christian Kuhn & Rüdiger Hehlmann

MARC

LEADER 00000caa a22000002c 4500
001 180247725X
003 DE-627
005 20230428182417.0
007 cr uuu---uuuuu
008 220518s2001 xx |||||o 00| ||eng c
024 7 |a 10.1517/14656566.2.7.1129  |2 doi 
035 |a (DE-627)180247725X 
035 |a (DE-599)KXP180247725X 
035 |a (OCoLC)1341460221 
040 |a DE-627  |b ger  |c DE-627  |e rda 
041 |a eng 
084 |a 33  |2 sdnb 
100 1 |a Reiter, Andreas  |d 1964-  |e VerfasserIn  |0 (DE-588)172629551  |0 (DE-627)697563766  |0 (DE-576)133488594  |4 aut 
245 1 0 |a AraC-based pharmacotherapy of chronic myeloid leukaemia  |c Andreas Reiter, Andreas Hochhaus, Ute Berger, Christian Kuhn & Rüdiger Hehlmann 
264 1 |c 2001 
300 |a 7 
336 |a Text  |b txt  |2 rdacontent 
337 |a Computermedien  |b c  |2 rdamedia 
338 |a Online-Ressource  |b cr  |2 rdacarrier 
500 |a Elektronische Reproduktion der Druckausgabe 
500 |a Gesehen am 18.05.2022 
520 |a In interferon-α (IFN) treated chronic phase chronic myeloid leukaemia (CML) patients, survival depends on individual risk profile and achievement of a complete haematological response (CHR) and a major cytogenetic response (MCR) (< 35% Philadelphia-chromosome-positive metaphases). The highest cytogenetic response rates have been achieved with the combination of IFN and low-dose sc. AraC (10 mg daily to 10 - 20 mg/m2 for 10 - 14 days/month). Whether the higher cytogenetic response rates are also associated with a significant improvement of survival still remains controversial. The different results obtained from large randomised and observational trials may be due to the numbers of patients enrolled, distribution of risk profiles and the treatment schedule, which is influenced greatly by the haematological and gastrointestinal toxicity of AraC. An oral formulation (YNK01), which is lipophilic and resistant to deamination, is currently under investigation. Clinically, it has similar activity, but toxicity leads to discontinuation of treatment in a considerable proportion of patients. The clinical benefits may therefore be outweighed by the dose-limiting toxicity for both application forms. Combinations with other drugs, e.g., STI571 or homoharringtonine, have shown promising early results in vitro and in vivo. 
650 4 |a AraC 
650 4 |a chronic myeloid leukaemia 
650 4 |a chronic phase 
650 4 |a interferon-α 
700 1 |a Hochhaus, Andreas  |d 1959-  |e VerfasserIn  |0 (DE-588)1107039339  |0 (DE-627)863321976  |0 (DE-576)474976130  |4 aut 
700 1 |a Berger, Ute  |e VerfasserIn  |0 (DE-588)1255399929  |0 (DE-627)1799635341  |4 aut 
700 1 |a Kuhn, Christian  |e VerfasserIn  |4 aut 
700 1 |a Hehlmann, Rüdiger  |d 1941-  |e VerfasserIn  |0 (DE-588)1037003489  |0 (DE-627)751737879  |0 (DE-576)390939463  |4 aut 
773 0 8 |i Enthalten in  |t Expert opinion on pharmacotherapy  |d Abingdon, Oxon : Routledge, Taylor & Francis, 1999  |g 2(2001), 7, Seite 1129-1135  |h Online-Ressource  |w (DE-627)324741901  |w (DE-600)2030119-4  |w (DE-576)302969330  |x 1744-7666  |7 nnas  |a AraC-based pharmacotherapy of chronic myeloid leukaemia 
773 1 8 |g volume:2  |g year:2001  |g number:7  |g pages:1129-1135  |g extent:7  |a AraC-based pharmacotherapy of chronic myeloid leukaemia 
856 4 0 |u https://doi.org/10.1517/14656566.2.7.1129  |x Verlag  |x Resolving-System  |z lizenzpflichtig  |3 Volltext 
951 |a AR 
992 |a 20220518 
993 |a Article 
994 |a 2001 
998 |g 1037003489  |a Hehlmann, Rüdiger  |m 1037003489:Hehlmann, Rüdiger  |d 60000  |d 61200  |e 60000PH1037003489  |e 61200PH1037003489  |k 0/60000/  |k 1/60000/61200/  |p 5  |y j 
998 |g 1255399929  |a Berger, Ute  |m 1255399929:Berger, Ute  |d 60000  |d 61200  |e 60000PB1255399929  |e 61200PB1255399929  |k 0/60000/  |k 1/60000/61200/  |p 3 
998 |g 1107039339  |a Hochhaus, Andreas  |m 1107039339:Hochhaus, Andreas  |d 60000  |d 61200  |e 60000PH1107039339  |e 61200PH1107039339  |k 0/60000/  |k 1/60000/61200/  |p 2 
998 |g 172629551  |a Reiter, Andreas  |m 172629551:Reiter, Andreas  |d 60000  |d 61200  |e 60000PR172629551  |e 61200PR172629551  |k 0/60000/  |k 1/60000/61200/  |p 1  |x j 
999 |a KXP-PPN180247725X  |e 4135879608 
BIB |a Y 
SER |a journal 
JSO |a {"person":[{"family":"Reiter","given":"Andreas","display":"Reiter, Andreas","role":"aut"},{"display":"Hochhaus, Andreas","given":"Andreas","family":"Hochhaus","role":"aut"},{"family":"Berger","display":"Berger, Ute","given":"Ute","role":"aut"},{"family":"Kuhn","display":"Kuhn, Christian","given":"Christian","role":"aut"},{"role":"aut","family":"Hehlmann","given":"Rüdiger","display":"Hehlmann, Rüdiger"}],"name":{"displayForm":["Andreas Reiter, Andreas Hochhaus, Ute Berger, Christian Kuhn & Rüdiger Hehlmann"]},"origin":[{"dateIssuedDisp":"2001","dateIssuedKey":"2001"}],"recId":"180247725X","title":[{"title":"AraC-based pharmacotherapy of chronic myeloid leukaemia","title_sort":"AraC-based pharmacotherapy of chronic myeloid leukaemia"}],"language":["eng"],"physDesc":[{"extent":"7 S."}],"id":{"eki":["180247725X"],"doi":["10.1517/14656566.2.7.1129"]},"type":{"media":"Online-Ressource","bibl":"article-journal"},"note":["Elektronische Reproduktion der Druckausgabe","Gesehen am 18.05.2022"],"relHost":[{"physDesc":[{"extent":"Online-Ressource"}],"part":{"year":"2001","pages":"1129-1135","volume":"2","text":"2(2001), 7, Seite 1129-1135","extent":"7","issue":"7"},"id":{"eki":["324741901"],"zdb":["2030119-4"],"issn":["1744-7666"]},"origin":[{"dateIssuedKey":"1999","publisherPlace":"Abingdon, Oxon ; London [u.a.]","publisher":"Routledge, Taylor & Francis ; Informa Healthcare","dateIssuedDisp":"1999-"}],"title":[{"subtitle":"EOP","title_sort":"Expert opinion on pharmacotherapy","title":"Expert opinion on pharmacotherapy"}],"type":{"media":"Online-Ressource","bibl":"periodical"},"pubHistory":["1.1999/2000 -"],"recId":"324741901","disp":"AraC-based pharmacotherapy of chronic myeloid leukaemiaExpert opinion on pharmacotherapy","language":["eng"],"titleAlt":[{"title":"EOP"}]}]} 
SRT |a REITERANDRARACBASEDP2001 

Ähnliche Einträge